Tag: rivaroxaban

New real-world study finds long-term rivaroxaban use resulted in fewer strokes...

Two-year results show rivaroxaban was associated with reduced stroke and systemic embolism versus warfarin, without altering risk of major bleeding. The study evaluated efficacy...

FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...
rivaroxaban

Rivaroxaban significantly reduces the risk of major amputation by 70% in...

Rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily also significantly (p=0.0003) reduces the risk of the composite outcome of...
rivaroxaban

ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...

The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...

European Medicines Agency issues positive opinion for rivaroxaban

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on a label update...
rivaroxaban

COMPASS study of Janssen’s rivaroxaban to end early for efficacy

The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Janssen) for the prevention of major adverse cardiac events, including cardiovascular...

AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients...

Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily dose of the drug and a P2Y12 inhibitor and...